OBI Pharma, Inc. (TPEX: 4174)

Market Cap	12.93B
Revenue (ttm)	69.55M
Net Income (ttm)	-2.11B
Shares Out	229.25M
EPS (ttm)	-9.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364,638
Average Volume	505,378
Open	56.10
Previous Close	55.80
Day's Range	55.40 - 56.60
52-Week Range	55.00 - 92.90
Beta	0.99
RSI	42.35
Earnings Date	Mar 25, 2025

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of so...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4174

Financial Performance

In 2023, OBI Pharma's revenue was 41.55 million, an increase of 781.96% compared to the previous year's 4.71 million. Losses were -1.05 billion, -35.16% less than in 2022.